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Abstract
Background: Effective translational biomedical research hinges on the operation of ‘biobanks,’ repositories that
assemble, store, and manage collections of human specimens and related data. Some are established intentionally to
address particular research needs; many, however, have arisen opportunistically, in a variety of settings and with a
variety of expectations regarding their functions and longevity. Despite their rising prominence, little is known about
how biobanks are organized and function beyond simple classification systems (government, academia, industry).
Methods: In 2012, we conducted the first national survey of biobanks in the U.S., collecting information on their
origins, specimen collections, organizational structures, and market contexts and sustainability. From a list of 636
biobanks assembled through a multi-faceted search strategy, representatives from 456 U.S. biobanks were
successfully recruited for a 30-minute online survey (72% response rate). Both closed and open-ended responses
were analyzed using descriptive statistics.
Results: While nearly two-thirds of biobanks were established within the last decade, 17% have been in existence
for over 20 years. Fifty-three percent listed research on a particular disease as the most important reason for
establishment; 29% listed research generally. Other reasons included response to a grant or gift, and intent to
centralize, integrate, or harmonize existing research structures. Biobank collections are extraordinarily diverse in
number and types of specimens and in sources (often multiple) from which they are obtained, including from
individuals, clinics or hospitals, public health programs, and research studies. Forty-four percent of biobanks store
pediatric specimens, and 36% include postmortem specimens. Most biobanks are affiliated in one or multiple ways
with other entities: 88% are part of at least one or more larger organizations (67% of these are academic, 23%
hospitals, 13% research institutes). The majority of biobanks seem to fill a particular ‘niche’ within a larger
organization or research area; a minority are concerned about competition for services, although many are worried
about underutilization of specimens and long-term funding.
Conclusions: Effective utilization of biobank collections and effective policies to govern their use will require
understanding of the immense diversity found in organizational features, including the very different history and
primary goals that many biobanks have.
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Background
Biobanks are repositories that assemble, store, and manage
collections of human specimens and related data. Although
they have existed in some form for over 60 years, their
recent surge in numbers, size, and prominence [1] has
focused attention on the changing nature of biomedical
research and relationships among investigators, research
participants, and the organizations that fund and manage
these entities [2-9]. This surge in numbers coincides with
success in sequencing the human genome in 2003, the sub-
sequent explosion of new bioinformatics technologies and
developments in next-generation sequencing [10,11], and
the vision of improved health through genomic medicine
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[12]. In short, effective translational biomedical research
discoveries depend upon the operation of biobanks.
Despite this reliance, we know little about biobanks.
The first attempt to catalog human tissue sources in the
U.S. was undertaken by the RAND Corporation [13],
coinciding with the first National Bioethics Advisory
Commission report on ethical and policy issues invol-
ving human biological materials [14]. Through its Hand-
book and the 12 case studies conducted four years later
[15], RAND provided information on specimen exis-
tence, location, and access, noting that not all forms of
repositories were captured. The legacy of the RAND
work is the classification of biobanks into three cate-
gories (government, academia, industry) that persists in
the literature [15]. Notwithstanding recent interest in
classifying biobanks [5,16], there is little empirical
research on the organization and functioning of bio-
banks that might inform a more nuanced, updated clas-
sification system.
There are several reasons for this dearth in empirical
research. Significant variation in biobank types leaves
scholars unable to agree upon a definition [5,17-25]. In
addition, no census or registry of biobanks exists from
which to draw representative samples for study. Thus,
while many authors have observed the importance of
organizational context for understanding biobank poli-
cies, it is understudied empirically [5,8,9,19,26-28]. In
fact, most empirical studies relevant to policy issues (for
example, informed consent, identifiability, return of
research results) have focused not on biobanks, but on
the views of external stakeholders [29-38].
To address this gap in knowledge, we sought to describe
U.S. biobanks in terms of their origins, specimen collec-
tions, organizational features, and market contexts. We
applied a systematic, multi-faceted strategy to develop a
list of biobanks in the U.S., and fielded a survey. Our find-
ings document extraordinary diversity, and present base-
line data upon which future analyses of organizational
change, policy, and regulatory frameworks may rest.
Methods
The U.S. Biobank Survey is part of a larger study of bio-
banks in the U.S., funded from 2010 to 2012 by grants
from the National Human Genome Research Institute
and a supplement to the University of North Carolina
(UNC) Clinical and Translational Science Award
(CTSA). The objectives were to examine the diversity of
biobanks’ organizational characteristics, policies, and
practices. For the purposes of our study, a biobank was
defined as ‘an organization that acquires and stores
human specimens and associated data for future
research use.’ Our work included conducting six qualita-
tive case studies, constructing a list of biobanks in the
U.S. [39], and piloting and administering a 30-minute
online survey. We collected data from U.S. biobank
representatives on how their biobanks operate, compo-
nents of organizational features identified in the litera-
ture, and the policies and practices biobanks have in
place that govern their relationships with the individuals
who contribute specimens and researchers who use
them. This study was approved by the UNC Institutional
Review Board.
Construction of the list of U.S. biobanks
Because there is no generally agreed upon definition of a
biobank and no reliable census of these heterogeneous
entities in the U.S., it is not possible to draw a represen-
tative sample for a national survey. In an attempt to cre-
ate a comprehensive list of U.S. organizations fitting our
definition of a biobank, we cast a wide net [39]. We
employed multiple search strategies, similar to those
used by RAND [13]. We searched articles listed in
PubMed for the year 2010 and current federally awarded
grant abstracts from National Institutes of Health
(NIH)’s RePORTER database; and performed a systema-
tic Google search consisting of two parts - an initial
search that found individual biobanks and a follow-up
search of lists and directories of biobanks that appeared
in the initial search. In addition, because a significant
portion of medical research is sponsored by medical
institutions and research institutes, and more recently
by NIH-sponsored CTSAs, we conducted searches on
American Association of Medical Colleges member web-
sites and on CTSA websites. Lastly, similar to RAND,
we communicated with other investigators involved in
biobank research to provide additional names, and in
one case, obtained a list of biobanks [28].
We used a wide variety of keywords in our multi-
faceted online searches, constructing nested Boolean
strings to account for the fact that some terms imply
the storage of specimens (for example, ‘biorepository’)
while other terms do not (for example, ‘collection’) [39].
Biobanks that did not aim to share specimens were
excluded, as were biobanks without some focus on
domestic research. If available information was ambigu-
ous, we contacted the organization for clarification.
We carefully recorded and cross-referenced all sources
so that we could both detect duplicates and identify the
strengths and weaknesses of different sources. Of neces-
sity, we restricted our focus to organizations for which
we could find at least minimal presence on the web.
That presence ranged from active marketing of the col-
lection, to being named as entities in academic institu-
tions or independent organizations where investigators
store research specimens, to being described in an orga-
nizational newsletter.
Figure 1 depicts the number of biobank names initially
identified, and the process by which we ultimately
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produced a list for survey recruitment. By eliminating
duplicates, we reduced our initial 1,741 names of possi-
ble biobanks to 894. We then endeavored to identify the
name and current email and postal mail addresses for
the director, manager, or other representative from each
biobank whom we would eventually recruit to take the
survey. We contacted, through email or telephone, these
representatives to confirm they had the appropriate
knowledge about the biobank to take our survey. In
many cases they did, but in some instances the person
we contacted nominated someone else in the organiza-
tion. We attempted to confirm the contact information
Figure 1 Number of biobank names initially identified, and process of determining eligibility for survey recruitment.
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of the nominated individual. During this process, we dis-
covered entities that did not fit our definition of a bio-
bank, were no longer in existence, or whose collections
had been transferred to another biobank; we marked
these cases as ineligible. Finally, there were some bio-
banks for which we were never able to discern adequate
contact information (either an email address or tele-
phone number), so we were forced to drop them from
our list of 894. Ultimately, we identified biobanks in 43
states plus the District of Columbia.
Survey development and pilot
Questions for the survey were based on results of our
six case studies, prior research studies (including surveys
of other types of organizations), and the organizational
sociology literature. We partnered with the UNC Odum
Institute for Research in Social Science for methodologi-
cal guidance on questionnaire design and on all aspects
of survey data collection. Given the measurement chal-
lenges we faced, we devoted a six-month period in 2011
to pilot testing all aspects of our survey plan.
For the pilot, we chose a purposive (non-random) sam-
ple of 100 biobanks from our list, ensuring that there was
representation of the four types of URL extensions in our
list (.com, .edu, .gov, and .net, or .org). We first notified
biobanks about the upcoming survey via a FedEx letter
explaining the study and the incentive for completion (a
$30 Amazon gift card). As described above, prior to
sending the letters, we emailed all biobanks selected for
the pilot and asked them to confirm that we had the cor-
rect name and contact information for a representative
with the knowledge to complete the survey. When neces-
sary, we followed up with phone calls to verify these
details. Using such thorough procedures, we were confi-
dent we were contacting the correct individual and were
able to customize the recruitment letters with the recipi-
ent’s name. Our goal was to get the potential respon-
dent’s attention in a professional way that motivated
them to watch for the survey invitation in their email
inbox and to complete the survey promptly.
Approximately four days after the FedEx letters were
delivered, we emailed invitations to the identified respon-
dent at each biobank. The email contained a hyperlink
which took the respondent directly to the survey. Of the
100 individuals we contacted, three replied that their orga-
nization did not meet our definition of a biobank and
were therefore ineligible. Of the remaining 97 biobanks,
77 completed the survey, for a response rate of 79%.
Results of the pilot study were used to revise and improve
the survey instrument in preparation for our main survey.
Survey of U.S. biobanks
Though we modified the survey questionnaire in
response to our pilot data, we changed little else in our
procedures for the main study. Excluding the 100 bio-
banks recruited for the pilot survey, our list included 681
biobanks (Figure 1). Of these, we had confirmed contact
information for 541; as in the pilot study, these biobanks
were recruited by letter sent via FedEx or USPS Express.
We did not receive responses to our email and telephone
requests to confirm their existence or contact informa-
tion from140 biobanks in our list. Without a confirmed
contact person or postal address, these biobanks were
recruited via email using the email address we had found
in our search. In February 2012, a few days after sending
the recruitment letters and emails, we emailed survey
invitations to these 681 banks. We used email reminders
and phone calls to prompt nonrespondents. In the pro-
cess of data collection, we discovered that an additional
45 biobanks (35 from the ‘confirmed contact’ group and
10 from the ‘unconfirmed contact’ group) were ineligible,
thus producing a total of 636 eligible biobanks in our
study. Upon conclusion of data collection in May 2012,
we had 456 completed surveys, representing a response
rate of 72%.
Differential response rates and nonresponse bias
As might be expected, we achieved a significantly higher
response rate among the biobanks with previously con-
firmed contact information than those without (81%
versus 34%, P < 0.001). However, only 20% of biobanks
(130 of 636) fell into the latter category, so our overall
response rate remained high. Assessing risk of nonre-
sponse bias requires observations on both responding
and nonresponding units [40]. The only additional,
potentially relevant information we have on nonre-
sponding biobanks is the domain portion of their web-
site URL (.com, .edu, .gov, and .net, or .org). We
examined response rates by domain and found no statis-
tically significant differences.
Table 1 shows the composition of the responding bio-
banks compared to the entire list. The responding
Table 1 Comparison of responding biobanks to master
list
Responding biobanks Master list
n % n %
Contact information confirmed prior to survey invitation?
Yes 413 91 507 80
No 43 9 130 20
Total 456 100 637 100
Domain portion of URL
.com 26 6 40 6
.edu 296 65 399 63
.gov 26 6 32 5
.org or.net 108 24 165 26
Total 456 100 637 100
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biobanks closely correspond to the distribution among
the four URL domain types.
Coding and analysis methods
Two types of open-ended questions were used in the sur-
vey. The first were stand-alone questions such as ‘What
is your title or role at [BIOBANK]?’ The second were
open-ended questions embedded in fixed-response ques-
tions, and were typically designed to allow respondents
to offer information beyond the fixed responses. For
example, we asked, ‘What is the main biomolecule [BIO-
BANK] isolates from specimens, if any?’ Fixed responses
included ‘DNA,’ ‘RNA,’ ‘Protein,’ ‘Other,’ and ‘None.’
Respondents who chose ‘Other’ were given an open-
ended text box to specify other biomolecules. A code-
book was developed for each open-ended question by at
least three of the authors (AGN, GEH, and RJC). All
open-ended responses were coded in a systematic man-
ner by a primary coder (AGN). Two secondary coders
(GEH and RJC) reviewed all codes proposed by the pri-
mary coder. When the secondary coders did not agree
with the primary coder’s choice of codes, the three coders
met and resolved inconsistencies through consensus.
Survey data were collected using Illume software version
4.7 (Datstat, Inc., Seattle, WA, USA). Data were analyzed
in SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
We present simple response frequencies and cross-tabula-
tions, with percentages where appropriate. Where percen-
tages do not add to 100, it is due to rounding. Most
variables are discrete; thus we used chi-square for tests of
statistical significance except when small cell sizes dictated
use of Fischer’s Exact Test.
Results and discussion
Origins of U.S. biobanks
Table 2 shows the reported dates of establishment for
biobanks in our survey. Though over half (59%) were
established since 2001, 17% have been in existence for
more than 20 years, with seven banks over 50 years old.
Respondents were asked to ‘check all that apply’ in a list
of reasons that their biobank might have been established,
and then asked to report the most important reason.
Table 3 shows that over half of the banks (53%) were
established primarily to facilitate research on a particular
disease or type of disease. Though we did not ask what
specific disease prompted establishment, it is clear from
reading responses to this and other open-ended survey
questions that by far the largest portion focus on cancer,
followed by neurological diseases (such as Alzheimer’s),
and HIV/AIDS. The second most frequent primary reason
for establishment was to facilitate research generally
(29%). The remaining 19% of biobanks were primarily
developed for various unique reasons specific to their cir-
cumstances, such as in response to a grant, to organize or
consolidate existing collections, or to store specimens for
others.
As shown in Table 3, we examined whether biobanks
established prior to the sequencing of the human genome
in 2003 were more likely to have been established to facili-
tate research on a particular disease compared to those
established after 2003 (59% versus 45%). After 2003,
although studying a particular disease was still the most
common reason for establishment, significantly more bio-
banks were created to facilitate research generally, com-
pared to years prior to 2003 (38% versus 22%, P < 0.01).
While there are likely multiple explanations for these
results, it is possible that the changing landscape of geno-
mic technology has facilitated a broadening of scope in
research pursuits so that biobanks are not as likely to limit
their work to one disease.
Specimen collections
The number of specimens currently in storage by the
responding biobanks ranged from tens to over 50 million.
The distribution is shown in Table 4. Due to a small num-
ber of very large banks, the mean number of specimens
reported was 461,396; the median was 8000. As can be
seen from Table 4, it is difficult to discern a ‘typical’ sized
collection; rather, biobank collections in the U.S. cover a
wide spectrum of very small to very large. It should be
noted that the survey question asked how many specimens
the bank currently stored, which may not be the best mea-
sure of size for some banks. Some respondents provided
comments at the end of the survey indicating that the
number of specimens they have in storage at any given
time varies greatly.
The number of specimens in storage can reflect dupli-
cate contributions and processed derivatives of contribu-
ted samples, so we also asked respondents approximately
how many individual contributors were represented
among their specimens in storage. Responses ranged from
just a few to 10 million. To get an idea of the number of
contributors typically represented in biobanks relative to
the number of specimens, we calculated the ratio of speci-
mens to contributors for each biobank. The values ranged
from 1 (one specimen per contributor) to 277. The mean
number was 12.6; however the distribution was skewed by
a small number of banks with large numbers of specimens
Table 2 Year of establishment
n %
1980 or earlier 30 7
1981 to 1990 46 10
1991 to 2000 109 24
2001 to 2010 249 56
2011 or later 13 3
Total 447 100
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per contributor. Thus, the modal response was 1 and the
median was 3.2 even though the mean was 12.6. Most bio-
banks (65%) had a ratio of 5 or fewer specimens to contri-
butors. Thus, it appears that most biobanks contain only a
small number of specimens from each contributor.
We asked respondents which type(s) of biological spe-
cimen(s) their bank stores. As shown in Table 5, serum
or plasma are the specimens most commonly stored
(77% of biobanks have them) with solid tissues following
close behind (69%). Fifty-five percent of biobanks store
whole blood, and 49% store peripheral blood cells or
bone marrow. Though cord blood or cord derivatives
were the least common among the categories we specifi-
cally asked about (11%), by coding the ‘other, please spe-
cify’ responses, we determined that 7% of biobanks store
pathological body fluids (such as the peritoneal fluid
that accumulates in ascites) and 3% store hair or toe-
nails - two categories we had not anticipated to be this
common.
As shown in Table 6, most biobanks (87%) store more
than one type of specimen; 8% store eight or more
types. The most frequent combination of types was
whole blood, plasma, and solid tissues. Banks with only
one type of specimen are most likely to be those which
only store solid tissue.
We asked respondents to identify the main biomole-
cule their bank isolates from specimens, if any. Nearly
50% said ‘DNA,’ 11% said ‘RNA,’ and 7% said ‘Protein.’
Twenty-four percent of respondents indicated ‘None.’
The 9% who chose ‘Other’ provided open-ended
responses to explain. Virtually all indicated that they
were unable to choose just one biomolecule because the
biobank isolates more than one in equal proportions
(most frequently DNA and others). The large percentage
of respondents who indicated their banks were isolating
DNA (and RNA) suggests that the majority of biobanks
are engaging in genetic research of one sort or another.
We wanted to determine biobanks’ sources for acquir-
ing specimens. As shown in Table 7, the two largest
sources of specimens are direct contribution by indivi-
duals (75%) and residual specimens from hospitals and
other clinical settings (57%). In fact, many (41%) include
specimens from both these sources, and only 8% do not
report either individuals or clinical settings as sources of
specimens. The third largest source of specimens is
research studies (13%). Other sources reported by a
small number of biobanks include vendors, organ or
body donation organizations, other repositories, or that
they acquired ‘orphaned’ collections (those which were
presumably abandoned by their original owners).
Respondents were asked whether specimens in their
collection represent any particular group(s) of indivi-
duals. Forty-four percent of biobanks store specimens
from children under the age of 18, though only 2% house
exclusively pediatric specimens. In 36% of biobanks, the
collection includes specimens collected postmortem,
including 9% which store exclusively postmortem speci-
mens, most of which are brain banks.
Table 3 Primary reason for establishment by date
Year established Facilitate research on a particular disease or type of disease Facilitate research generally Other reason Total
n % n % n % n %
Before 2003 137 59 50 22 45 19 232 54
2003 or later 87 45 73 38 34 18 194 46
Total 224 53 123 29 79 19 426 100
Χ2 = 13.71, P < 0.01
Table 4 Number of specimens in storage
n %
Less than 500 63 15
500 to 999 28 7
1000 to 1999 31 7
2000 to 4999 54 13
5000 to 9999 44 10
10,000 to 49,999 70 16
50,000 to 99,999 38 9
100,000 to 499,999 65 15
500,000 + 33 8
Total 426 100
Mean: 461,396; standard deviation: 3,324,096; median: 8000; interquartile
range: 1,200 to 76,000; skewness: 12.76; kurtosis: 181.
Table 5 Types of specimens in storage (check all that
apply)
Percentage of biobanks storing specimens of this type n %
Serum or plasma 349 77
Solid tissue specimens, including paraffin-embedded, frozen,
or other
315 69
Whole blood 251 55
Peripheral blood cells or bone marrow 222 49
Cell lines 162 36
Saliva or buccal cells 155 34
Urine or stool 138 30
Cerebral spinal fluid 85 19
Cord blood or cord blood derivatives 51 11
Other biological specimens 40 9
Pathological body fluids 30 7
Hair/toenails 14 3
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As shown in Table 8, 76% of respondents indicated their
biobank’s specimens come primarily from individuals with
a particular disease or type of disease, and an equal pro-
portion reported that their specimens come primarily
from patients in a specific hospital or clinic. Over half
(60%) endorsed both ‘individuals with a particular disease
or type of disease’ and ‘patients from specific hospital(s) or
clinic(s).’ It is not clear from our data whether this repre-
sents two descriptors of the same group (patients in parti-
cular clinical settings who have a particular disease) or
whether these biobanks have different sub-collections,
though we believe the former explanation is most logical.
Similarly, 34% of respondents reported both that their bio-
bank’s specimens are primarily drawn from clinical trials
patients and from specific hospital or clinical settings. An
equal fraction (34%) endorsed both ‘participants in clinical
trials’ and ‘patients with a particular disease or type of
disease.’
Organizational characteristics
Only 5% of responding biobanks are for-profit organiza-
tions. Seven percent are incorporated. Regardless of
organizational form, 80% have internal oversight boards
of some kind. We asked whether each biobank is ‘part
of a network of biobanks.’ Sixteen percent indicated
they were and then filled in the name of the network.
Based on detailed review of these open-ended responses,
it is clear that respondents interpreted ‘network’ broadly.
Responses included programs, registries, cooperative
groups, multi-site studies, and consortia that were NIH
sponsored, state-sponsored and population based, intra-
and inter-institutional, and national and international.
A few banks listed more than one network.
Most biobanks are affiliated in one or multiple ways
with other organizations. Determining the presence and
nature of biobanks’ affiliations or locations within larger
organizations proved very difficult - so difficult, in fact,
that it took us three attempts to develop a suitable ques-
tion. Following the pilot study, we rewrote the survey
questions about being part of a larger organization.
Despite our best efforts, it became clear midway through
our data collection effort that we still had not asked the
questions in a way respondents understood as we
intended. For example, we found biobanks that were
clearly part of universities whose respondents identified
the bank as an ‘independent organization.’ For this reason,
we clarified the wording of our survey question (adding
‘such as a university, a hospital, government, a research
institute, or any other type of larger organization’ to our
original question wording of ‘Is your biobank an indepen-
dent organization or part of some larger organization?’).
We re-contacted the 121 biobanks who had responded
that they were ‘independent’ prior to this modification in
order to ensure they were properly classified. Through
these efforts, we determined that 88% of responding bio-
banks were part of larger organizations and only 12% were
independent in the ways we intended to use the terms.
Further characterizations of biobanks within larger
entities were equally challenging. When biobanks were
part of larger organizations, we asked respondents to
indicate the nature of the larger organization(s), using a
provided list of eight organizational types and space to
write in others. Among biobanks that are part of one or
more larger organizations (which we call ‘embedded’),
Table 9 shows the percentage that checked each type of
organization. Clearly the most frequent affiliation of a
biobank is within an academic institution (78% of
embedded banks). Hospitals were reported as a parent
organization for 27%, and 15% were part of a research
Table 6 Number of types of specimens in storage
n %
1 58 13
2 59 13
3 81 18
4 62 14
5 66 15
6 50 11
7 38 8
8+ 36 8
Total 453 100
Table 7 Acquisition of specimens (check all that apply)
Percentage of biobanks which get specimens from... n %
Direct from individuals donating them 343 75
Residual specimens acquired from clinical care in hospitals, clinical laboratories, or pathology departments 261 57
Research 60 13
Residual specimens from public health departments or programs 19 4
Vendors 8 2
Organ/body donation organization 7 2
Other repositories 7 2
Other 6 1
Orphaned collections 4 1
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institute. About a quarter (28%) of all biobanks are part
of more than one larger organization. Table 10 provides
details. By far the most common situation of multiple
affiliation is for a biobank to be affiliated with an aca-
demic institution and also with another organization - a
hospital being a second affiliation for more than half
(73%) of academic biobanks with multiple affiliations.
The next most common multiple affiliation is within an
academic institution and also a research institute (34% of
biobanks affiliated with academic institutions are also
part of a research institute).
Very few non-academic biobanks are embedded within
more than a single larger organization. Most are solely
within a single larger entity, and it is most likely to be
the federal government (29%), or a hospital or research
institute (18% each).
For many biobanks, being embedded within a larger
organization is critical to its financial structure. Together
with the federal government, the larger organizations
named by biobanks are the most common and largest
sources of funding. Tables 11 and 12 show the results of
our questions regarding the bank’s largest source of cur-
rent funding (Table 11) and funding provided within the
past 5 years (or since establishment for biobanks younger
than 5 years) by a list of possible sources (Table 12). The
federal government is the largest funding source for 36%
of biobanks and provided some amount of funding in the
past 5 years to 57% of responding biobanks. The larger
organization is the largest current source for 30% of bio-
banks and provided some amount of funding for 59% of
biobanks within the past 5 years. Fees for services (primary
for 11% and within-5-year source for 44%) and funding
from individuals or foundations (primary for 10% and
within-5-year source for 40%) were also common. In a
separate question, we asked biobanks that are not part of
government agencies but nonetheless receive government
funding to indicate the extent to which they are dependent
on government funding to maintain operation. Among
these, 34% are completely dependent, 36% are mostly
dependent, 22% are somewhat dependent, and only 8% are
not at all dependent on government funding.
Taken together, these data on embeddedness and mul-
tiple affiliations demonstrate the inadequacy of simple
classifications of biobanks as ‘government, academia, or
industry.’ For example, the approximately 300 biobanks
that identify themselves as ‘academic’ have essentially
the same degree of diversity in organizational features
(such as size of collection and sources of acquisition) as
the full set of responding biobanks (data not shown).
Market context and sustainability
To learn about the ‘market’ in which biobanks operate,
we asked respondents whether their biobank is in compe-
tition with other biobanks to provide specimens and data
to researchers. Only 14% said yes. Of these 57 biobanks,
only 4 said there is ‘a great deal’ of competition; 29 (51%)
said there is a moderate amount of competition, and 24
(42%) said there is very little competition. Overall, then,
Table 8 Specimen contributors (check all that apply)
Percentage of biobanks reporting that their specimens are drawn primarily from... n %
Individuals with a particular disease or type of disease 335 76
Patients from specific hospital(s) or clinic(s) 331 76
Participants in a cohort study 184 40
Participants in clinical trials 180 39
Individuals from a specific geographic area (including community-based biobank) 122 27
Table 9 Type of larger organizations biobank is part of
(check all that apply)
n %
Academic institution 307 78
Hospital or health care organization 105 27
Research institute 60 15
Federal government 38 10
Disease or health advocacy organization 19 5
State government 17 4
Philanthropic organization 11 3
Corporation 10 3
Other 7 2
Consortium 5 1
Note: Table includes only biobanks which are embedded in at least one larger
organization (n = 394)
Table 10 Number of types of organizations biobank is
part of, by academic affiliation
With academic
affiliation
Without academic
affiliation
n % n %
0 (independent) 0 0 54 38
1 189 62 77 55
2 71 23 10 7
3 38 12 0 0
4 5 2 0 0
5 3 1 0 0
6 1 0 0 0
Total 307 100 141 100
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only 33 (8%) of responding biobanks reported that they
experience a great deal or a moderate amount of compe-
tition. For-profit biobanks are significantly more likely to
report being in competition than others (61% versus 12%,
P < 0.001). It would appear that most biobanks fill a par-
ticular ‘niche’ within their larger organization or research
area and generally do not seem concerned about losing
their ‘market.’ This sentiment is echoed in responses to
questions about demand for biobank products and ser-
vices, where 51% of respondents report that demand for
their bank’s services has increased in the past 2 years.
Only 6% said demand decreased, and 43% said it stayed
about the same.
While concerns about competition and demand were
not substantial, many respondents did express concern
about sustainability, typically linked with financial needs.
Forty-one percent consider this a major concern, 31% a
moderate concern, and 20% a minor concern; only 9%
report it is not at all a concern. As might be expected,
running out of funding is significantly less likely to be a
major or moderate concern for biobanks which rely on
sales (of specimens or other products) and fees for ser-
vices as their primary funding source than it is for
others (58% versus 74%, P < 0.01). A final marketplace
concern for some biobanks is the underutilization of
their specimen collections. Thirteen percent report that
this is a major concern, 28% say it is a moderate con-
cern, for another 28% it is a minor concern, and 31%
said it is not at all a concern.
Conclusions
In this paper we describe both the process by which we
conducted a national U.S. biobank survey and results
from that survey. As the first survey of its kind in the U.
S., our study has inevitable limitations, particularly in
attempting to characterize such a diverse universe of
organizations. Given the lack of a comprehensive regis-
try of biobanks from which to sample, our survey can-
not claim statistical inference to all U.S. biobanks.
However, our systematic, multi-faceted searches for
online presence produced a reasonable approximation of
all biobanks in existence in the U.S. at this time. We
achieved a high survey response rate, but we cannot
speak to whether our results would have been different
had the other 28% of banks responded. The only signifi-
cant bias in survey response was whether we had estab-
lished contact with a potential respondent; this was not,
however, related to the biobank’s URL domain. (The
various URL domains were represented in appropriate
proportions among our responding biobanks.) Finally,
we document that over half of our respondent banks
were established since 2001. While we believe this
reflects a burgeoning industry, it does not take into
account survival bias. There were undoubtedly some
biobanks that were in existence before 2001 but did not
survive to be included in our list.
Despite these limitations, the documentation of tre-
mendous diversity in the origins, collections, organiza-
tional features, and market contexts of biobanks in the
U.S. is important. This diversity raises questions about
the utility of the simple classification schemes employed
in the past. Our results strongly suggest that a multi-
dimensional classification scheme is needed that will
enable nuanced attention to the policies and practices
that biobanks employ to carry out their work.
Biobanks are not a new phenomenon. However, the
steep rate of increase in establishment in the last decade
is a sign of rapid change, and likely also contributes to
the organizational diversity we document. Undoubtedly,
some of this increase may be attributed to advances in
genomics and bioinformatics and increased emphasis on
translational research, all of which stimulate the demand
for stored specimens and associated data. In fact, our
survey results indicate that the majority of biobanks are
Table 11 Largest current source of funding
n %
Federal government 158 36
The larger organization biobank is a part of 133 30
Fees for services 49 11
Individuals or foundations 43 10
State government 11 2
Clinical and Translational Science Award 11 2
Sale of specimens 10 2
Other 10 2
Sale of other products 9 2
The network to which biobank belongs 5 1
None 4 1
Total 443 100
Table 12 Funding sources in past 5 years (check all that
apply)
Percentage of biobanks which received any funding
from...
n %
The larger organization biobank is part of 269 59
Federal government 260 57
Fees for services 200 44
Individuals or foundations 182 40
Sale of specimens 68 15
State government 53 12
Clinical and Translational Science Award 47 10
The network to which biobank belongs 33 7
Sale of other products 30 7
Interest or dividends 15 3
Licensing technologies 14 3
Local government 5 1
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storing specimens that can be used for genetic or geno-
mic research, which raises particular concerns regarding
privacy and identifiability [41]. Our prior work on
genetic researchers’ perspectives documents their reluc-
tance to discard samples [42], and preliminary data ana-
lysis from our case studies and open-ended comments
from our survey confirm this belief in the tremendous
value of research specimens.
Findings that document highly diverse numbers, types,
and sources of specimen collections raise questions
regarding how biobanks should be managed and gov-
erned. For example, while the large number of banks
that collect and retain residual clinical specimens is
unsurprising, it is nevertheless important because of
recent controversies regarding whether and how consent
for such specimens should be obtained [41,43-45]. Per-
haps more surprising is our finding that such a large
number of biobanks contain pediatric and postmortem
specimens in their collections, along with specimens
from other sources. While biobanks with exclusively
pediatric or postmortem specimens (9% and 2% of our
surveyed biobanks, respectively) typically adopt particu-
lar guidelines for human subjects protections, it is less
clear how these specimens might impact governance in
mixed-source collections.
Most biobanks are embedded in one or more other
entities. The fact that over one-quarter of surveyed bio-
banks are part of more than one larger organization cre-
ates significant classification problems. Embeddedness
makes it harder to understand how policies and prac-
tices are enacted, as it may be unclear where the locus
of decision-making resides. More research is needed to
understand the complexity of biobanks’ relationships
with other organizations and how these relationships
impact their work.
The finding of remarkable diversity in organizational
characteristics is typical of an emerging industry in the
early and rapidly evolving stages of development [46]. In
fact, a striking finding of rapid turnover in this industry
was actually a by-product of our work to create the bio-
bank list (for which the majority of biobanks classified
as ineligible after correspondence with each biobank’s
potential respondent was due to the bank no longer
being in operation). Organizational theory would predict
that new, innovative forms of biobanks will arise and
survive based on a variety of both internal and external
factors [46], that these factors may be studied to under-
stand organizations’ survival strategies [47,48], and that
some forms will become institutionalized over time
[49,50].
Capturing the full range of organizational configura-
tions will be important moving forward as the market
for biobank services is likely to increase in complexity,
and possibly in the mixture of interrelated forms such
as public-private partnerships, vertical and horizontal
networks, and other types of out-sourcing or combined
practices. It is difficult to predict the nature and extent
of change for biobank organizations. However, given
that the majority of respondents in our study expressed
concern about funding and underutilization, one sce-
nario is that biobanks will coalesce around a limited
number of organizational forms in order to maximize
survival, and that those with similar missions may join
together to form larger collections, or join networks or
consortia to endeavor to stabilize funding and increase
utilization. Regulatory agencies, professional associa-
tions, or influence exerted by more established biobanks
on latecomers might all promote convergence of organi-
zational types. Conversely, a different scenario would
predict that biobanks are driven toward increased diver-
sity by rapid changes in technology, customization, and
the need to differentiate to address more particularized
markets. Innovation might be found more in indepen-
dent biobank markets where fewer forces may exist to
compel banks to be more similar [49]. These are impor-
tant topics for future research, especially as they relate
to utilization of biobank resources and ensuring that
biobanks meet their promise as effective vehicles for
translational research.
As part of the research enterprise, biobanks, like the
researchers who depend on their services and speci-
mens, need guidance informed by knowledge of their
practices and challenges. The complex organizational
landscape of biobanking requires policies as nuanced as
the biobanks themselves, whether those policies address
subject protection or privacy, or the advancement of
research goals. Given different stakeholders and mis-
sions, it is unlikely that one-size policies will fit all bio-
banks, but attention to organizational diversity is critical
for the promotion of appropriate and effective biobank
governance.
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